Loading organizations...
§ Private Profile · Eclipse House, Sittingbourne Rd, Maidstone, United Kingdom
Michelson Diagnostics is a technology company.
Michelson Diagnostics specializes in advanced medical imaging, using Optical Coherence Tomography (OCT) for dermatology. Their VivoSight product provides high-resolution, non-invasive imaging of skin tissue. This establishes them as a leader in practical OCT systems, offering precise diagnostics for various skin conditions.
The company was founded in March 2006 by five physicists and engineers. Their collective expertise in laser scanning led to the insight: leveraging OCT to transform dermatological assessment. This technical foundation drove rapid development and regulatory approval of their core imaging technology.
Michelson Diagnostics serves dermatologists and medical practitioners requiring real-time, detailed skin visualization. Their mission is to advance non-invasive diagnostic imaging, improving clinical outcomes. They aim to expand their innovative OCT solutions, providing accurate and early diagnostic support for dermatology.
Michelson Diagnostics has raised $11.4M across 6 funding rounds.
Michelson Diagnostics has raised $11.4M in total across 6 funding rounds.
Michelson Diagnostics is a UK-based medical device company specializing in multi-beam Optical Coherence Tomography (OCT) technology for dermatology.[1][2][3] Its flagship product, the VivoSight OCT scanner (including models like VivoSight Dx and Dx Pro), is a point-of-care device that provides high-resolution, real-time cross-sectional images of skin tissue up to 1-1.5 mm deep, enabling clinicians to diagnose and monitor conditions like non-melanoma skin cancer (NMSC) without biopsies.[1][2][4][6] It serves dermatologists, researchers, and clinicians by solving the problem of inaccurate surface-based assessments, allowing earlier, more precise treatment decisions and reducing invasive procedures.[1][6]
The company generates revenue from VivoSight's commercial application in NMSC diagnosis, with ongoing advancements like upgraded software for lesion analysis and angiographic imaging to visualize morphologic changes.[1][6] Growth includes product launches (e.g., VivoSight Dx in 2015) and design enhancements for better user experience, positioning it as a leader in non-invasive skin imaging.[2]
Michelson Diagnostics was founded in March 2006 in Orpington, UK, by five physicists and engineers expert in laser scanning, initially to develop a hand-held cancer scanner using OCT technology.[3][5][6] In just four years, the team built, tested, and secured regulatory clearance for their system, demonstrating rapid progress from concept to market.[3] Early focus was on multi-beam OCT for dermatology, leading to the launch of the VivoSight scanner, with pivotal upgrades like new software in 2014 for skin lesion investigation and the VivoSight Dx at a 2015 dermatology congress.[1][2]
CEO Jon Holmes has emphasized providing cutting-edge tools for accurate skin condition diagnosis, building on collaborations with dermatologists to refine usability and patient experience.[1][2]
Michelson Diagnostics rides the trend toward non-invasive, real-time diagnostics in dermatology, fueled by rising NMSC incidence and demand for precision medicine.[1][4] OCT's timing aligns with advances in laser optics and AI-enhanced imaging, outpacing traditional biopsy methods amid growing tele-dermatology and point-of-care needs.[2][6] Market forces like aging populations and skin cancer prevalence favor its expansion, influencing the ecosystem by setting OCT as a dermatology standard and enabling research into epithelial diseases.[1][6]
Michelson Diagnostics is poised to expand VivoSight's adoption with Dx Pro's angiographic capabilities, targeting broader clinical trials, academic research, and global dermatology markets.[6] Trends like integrated AI for automated analysis and portable OCT will shape its path, potentially evolving into multi-application platforms for other epithelial cancers. Its influence may grow by partnering with medtech firms, solidifying non-invasive imaging as dermatology's core tool and enhancing early detection outcomes.[1][6]
Michelson Diagnostics has raised $11.4M across 6 funding rounds. Most recently, it raised $3.0M Series B in February 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2015 | $3M Series B | Andy Boyes | Edge VC, Kent County Council | Announced |
| Mar 13, 2012 | $960K Venture Round | — | — | Announced |
| Mar 1, 2012 | $950K Series U | — | Edge VC | Announced |
| Jan 3, 2012 | $3M Venture Round | — | Catapult Ventures, Octopus Investments | Announced |
| Mar 17, 2011 | $480K Venture Round | Octopus Investments | — | Announced |
| Oct 1, 2010 | $3M Series A | Octopus Investments | Edge VC, Catapult Ventures | Announced |
Michelson Diagnostics has raised $11.4M in total across 6 funding rounds.
Michelson Diagnostics's investors include Andy Boyes, Edge VC, Kent County Council, Catapult Ventures, Octopus Investments.